[1] | Robert YS, Nancy M, Katsuhiro H, Donald H, Victor DG, Christina AR, Hirohito T and Sherri OS (2012): Host immune status and incidence of hepatocellular carcinoma among subjects infected with hepatitis C virus: A nested case-control study in Japan. Gut; 48:605. |
[2] | Bertino G, Demma S, Bertino N and Ardiri A (2014): Management of hepatocellular carcinoma: an update at the start of 2014. J Gastroint Dig System; 4: 178. |
[3] | Morcos NY, Ekram ZI, Mohamed SM, Mamdouh MA and Abdel-Halim AH (2012): Evaluation of biomarkers for the detection of hepatocellular carcinoma in patients with hepatitis C virus. Journal of Experimental and Integrative Medicine; 2(4):321-329. |
[4] | Hafez S, El Sebai A, Abd-AL Aziz M, Abdel-Baky M, El Maraghy MO, Khalifa MO and Musa NI (2013): Alfa-fetoprotein L3 subfraction and osteopontin: Novel markers for the diagnosis of hepatocellular carcinoma. Journal of American Science; 9(3). |
[5] | Della C and Colombo M (2012): Surveillance for hepatocellular carcinoma. Semin Oncology; 39: 384-398. |
[6] | Hsu CY, Lee YH, Hsia CY, Su CW and Lin HC (2013): Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona. Hepatology; 57(1):112-9. |
[7] | Finn RS (2013): Overview and description of hepatocellular carcinoma. Clin Adv Hematol Oncology; 5: 4–7. |
[8] | Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC and Di Bisceglie AM (2010): Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for early detection of hepatocellular carcinoma. Gastroenterology; 138(2):493-502. |
[9] | Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G and Bertino N (2012): Hepatocellualar carcinoma serum markers. Semin Oncology; 39: 410-433. |
[10] | John DC, Novak P, April DL, Nelly A, Donald R, Paul LS, Michael DR, Bernard WF, Lehman-McKeeman LD and Nathan JC (2014): Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Science; 59:365–374. |
[11] | Lin CL and Kao JH (2013): Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatology; 28: 10-17. |
[12] | Baffy G, Brunt EM and Caldwell SH (2013): Hepatocellular carcinoma in nonalcoholic fatty liver disease: an emerging menace. J Hepatology; 56:1384–1391. |
[13] | Abdel-Rahman NZ, Alam El-Din HM, Bahnassy AA, Zayed NA, Waleed SM, El-Masry SH, Gouda SK and Esmat G (2010): Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4, Comparative Hepatology; 9:1. |
[14] | Huo TI, Wu JC and Lin HC (2004): Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transpl., 10(12):1507-13. |
[15] | Santambrogio R, Salceda J, Costa M, Kluger MD, Barabino M and Laurent A (2013): External validation of a simplified BCLC staging system for early hepatocellular carcinoma. Eur J Surg Oncology; 39(8):850-7. |
[16] | Nault J C, Guyot E and Laguillier C (2013): Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis. Cancer Epidemiol Biomarkers Prev., 22: 1343-52. |
[17] | Leow CC, Coffman K, Inigo I, Breen S, Czapiga M and Soukharev S (2012): MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncology; 40:1321–30. |
[18] | Linares PM, Chaparro M and Gisbert JP (2013): Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease: a review. Journal of Crohn’s and Colitis; vol. 8, no. 3, pp. 183–190. |
[19] | Zhu AX, Duda DG, Sahani DV and Jain RK (2013): HCC and angiogenesis: possible targets and future directions. Nat Rev Clinical Oncology; 8:292–301. |
[20] | Matsubara T, Kanto T and Kuroda S (2013): TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlate with angiogenesis. Hepatology; 57(4):1416–1425. |
[21] | Sharma BK, Srinivasan R and Kapil S (2013): Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma. Mol Cell Biochem., 383(1–2): 103–112. |
[22] | Sanz-Cameno P, Trapero-Marugan M, Chaparro M, Jones EA and Moreno-Otero R (2010): Angiogenesis: From chronic liver inflammation to hepatocellular carcinoma. J Oncology; 272170. |
[23] | Cascone T and Heymach JV (2012): Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword? J Clin Oncology; 30(4):441–444. |
[24] | Gerald D, Chintharlapalli S, Augustin HG and Benjamin LE (2013): Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Research; 73(6):1649–1657. |
[25] | Chen HH, Weng BQ, Cheng KJ, Liu HY, Wang SQ and Lu YY (2014): Effect of the vascular endothelial growth factor expression level on angiopoietin-2-mediated nasopharyngeal carcinoma growth. Vasc Cell; 6: 4. |
[26] | Sallinen H, Tommi H, Koponen J, Veli-Matti K, Heinonen S, Ylä-Herttuala S and Maarit AS (2014): Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer; 14:696. |
[27] | Sarah Y and Robert R (2010): Regulation of endothelial barrier function. Integrated system physiology: From molecule into function. ISBN: 978-1-61504-120-6. |
[28] | Fagiani E1 and Christofori G (2013): Angiopoietins in angiogenesis. Cancer Lett., 1;328(1):18-26. |
[29] | Badran HM, Elshenawy NA, Elsaiid MH, Rewisha EA (2009): Serum angiopoietin-2 in Egyptian patients with HCV induced liver cirrhosis and hepatocellular carcinoma. Gut; 58 (Suppl II) A492. |
[30] | Herna´ndez-Bartolome´ A´, Lo´ pez-Rodrı´guez R, Rodrı´guez-Mun˜oz Y, Martı´n-Vı´lchez S and Borque MJ (2013): Angiopoietin-2 serum levels improve noninvasive fibrosis staging in chronic hepatitis c: a fibrogenic-angiogenic link. PLOS One; 8(6): e66143. |
[31] | Abd-El-Moety HA, Magour GH, Maharem DA and Hussein AM (2011): Evaluation of serum angiopoietin-II in HCV related glomerulonephritis. Alexandria Journal of Medicine; 47, 97–103. |
[32] | Davis JS, Yeo TW and Piera KA (2010): Angiopoietin-2 is increased in sepsis and inversely associated with nitric oxidedependent microvascular reactivity. Critical Care; vol. 14, no. 3, article R89. |
[33] | David S, Mukherjee A and Ghosh CC (2012): Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis. Critical Care Medicine; vol. 40, no. 11, pp. 3034–3041. |
[34] | Engin H, Ustundag Y, Tekin IO, Gökmen A, Ertop Ş and İlikhan SU (2012): Plasma concentrations of angiopoietin-1, angiopoietin-2 and Tie-2 in colon cancer. Eur Cytokine Netw., 23: 68-71. |
[35] | Ping L, Quanyong H, Chenqun L and Liyuan Q (2015): Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer. Int J Clin Exp Pathology; 8(1):660-664. |
[36] | Diaz-Sanchez A, Matilla A, Nuñez O, Raquel L, Alejandro F, Rincón D, Rocio C, Bañares R, and Gerardo C (2013): Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma. Scand J Gastroenterol; Vol. 48, No. 3 , Pages 334-343. |
[37] | Kelley RK, Siu LL and Van Loon K (2014): Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hepatocellular carcinoma (HCC) cohort. J Clin Oncology; 32(Suppl; abstr 2540):5s. |
[38] | Globocan 2008, International agency for Research on cancer –WHO: Cancer incidence, mortality and prevelance worldwide in 2008. GLOBOCAN 2008 (IARC), Section of Cancer Information. |
[39] | Zhao YJ, Ju Q and Li GC (2013): Tumor markers for hepatocellular carcinoma. Mol Clin Oncology;1, 593-8. |
[40] | Nair S, Shiv Kumar K and Thuluvath PJ (2002): Mortality from hepatocellular and biliary cancers: changing epidemiological trends. Am J Gastroenterology; 97(1): 167-171. |
[41] | Blum HE (2002): Molecular targets for prevention of hepatocellular carcinoma. Dig Dis.,20(1):81-90. |
[42] | Sakisaka S, Watanabe M, Tateishi H, Harada M, Shakado S, Mimura Y, Gondo K, Yoshitake M, Noguchi K and Hino T (1993): Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia: immunohistochemical evidence. Hepatology; 18(6):1357-62. |
[43] | Pratt D and Kaplan M (1999): Evaluation of the Liver A: Laboratory Tests. In: Schiff's Diseases of the Liver, Eighth Edition (Eds), Lippincott Williams Wilkens, Philadelphia. p.205. |
[44] | Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M and Primignani M (2005): Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology; 41(3):553-8. |
[45] | Shrelock S and Dooley J (2002): Malignant liver tumors. In Disease of the liver and biliary system (11th edition), Published by Blackwell Company, London. Chapter 31; P 537- 563. |
[46] | Kew MC (2002): Hepatic tumors and cysts. Gastrointestinal and liver disease (6th edition), Philadelphia: W.B. Saunders; P 2007-2020. |
[47] | Sugiyama M, Kanno T, Ohkubo A, Muto Y, Murata K and Ueno Y (1992): The clinical usefulness of the molar ratio of branched-chain amino acids to tyrosine (BTR) in discriminating stage of chronic liver diseases. Rinsho Byori., 40:673-678. |
[48] | Mittal A, Sathian B and Chandrashekharan N: (2008): Diagnostic significance of alpha fetoprotein in carcinomas of liver and biliary tract - a comparative study from western region of nepal. Asian Pac J Cancer Prev.,12, 3475-8. |
[49] | Guan C-N, Chen X-M and Lou H-Q (2012): Clinical significance of axin and β-catenin protein expression in primary hepatocellular carcinomas. Asian Pac J Cancer Prev., 13, 677-81. |
[50] | Gad A, Tanaka E, Matsumoto A, Serwah A, Attia F and Hassan A (2005): Ethnicity affects the diagnostic validity of alpha-fetoprotein in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology; 1: 64-70. |
[51] | Hussein MM, Ibrahim AA, Abdella HM, Montasser IF and Hassan MI (2008): Evaluation of serum squamous cell carcinoma antigen as a novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients. Indian Journal of Cancer; 45 (4): 167-172. |
[52] | Scholz A, Rehm VA and Rieke S (2007): Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and HCC. Am J Gastroenterology; 102 (11):2471-81. |
[53] | Hunter S, Hassab-Allaah MS, El-Ansary MA and El Shanawani MH (2010): Significance of Angiopoietin-2 as a Serum Marker for Hepatocellular Carcinoma. Journal of American Science; 66:1114-1123. |
[54] | Hernández JC, Samada M, Roque A, Cruz Y, Howland I and Fernández I (2011): Diagnostic value of alpha-fetoprotein for hepatocellular carcinoma Biotecnología Aplicada; 28: 34-39. |